Metastatic squamous non-small cell lung cancer
Clinical trials for Metastatic squamous non-small cell lung cancer explained in plain language.
Never miss a new study
Get alerted when new Metastatic squamous non-small cell lung cancer trials appear
Sign up with your email to follow new studies for Metastatic squamous non-small cell lung cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug rilvegostomig takes on keytruda in lung cancer showdown
Disease control Recruiting nowThis phase 3 study compares two immunotherapy drugs—rilvegostomig and pembrolizumab (Keytruda)—each combined with standard chemotherapy, as a first treatment for people with advanced squamous non-small cell lung cancer that has a specific protein (PD-L1). About 880 participants w…
Matched conditions: METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Smart bombs for lung cancer: new ADC drugs enter trial
Disease control Recruiting nowThis phase 2 trial tests two antibody-drug conjugates (ADCs) — R-DXD and I-DXD — against standard chemotherapy in 144 people with advanced squamous non-small cell lung cancer that has worsened after initial treatment. ADCs are like guided missiles that deliver a cancer-killing dr…
Matched conditions: METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug cocktail aims to extend life in tough lung cancer
Disease control Recruiting nowThis Phase 3 trial tests whether adding a maintenance drug (sacituzumab tirumotecan) after initial chemo-immunotherapy improves survival in people with metastatic squamous non-small cell lung cancer. About 851 participants will receive pembrolizumab plus chemotherapy, then either…
Matched conditions: METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC